Precision BioSciences Reports Positive Phase 1 PBGENE-HBV Data and Q3 2026 Financial Results

Precision BioSciences said Phase 1 results for PBGENE-HBV support advancing to Phase 2, with initial dosing at 0.4 mg/kg expected in the first quarter of 2027. The company reported no dose-limiting toxicities across 59 administrations in 25 patients, alongside evidence of durable pgRNA loss and cccDNA reduction. Third-quarter 2026 net loss narrowed to $7.6 million from $21.8 million a year earlier; cash totaled $108 million, which the company expects to fund operations through 2028. Precision also presented ELIMINATE-B study data at the AASLD meeting on November 8, 2026.